"...we had everything before us, we had nothing before us...in short, the period was so far like the present period, that some of its noisiest authorities insisted on being received, for good or for evil, in the superlative degree of comparison only."
You know, I enjoy Charles Dickens far more now than I did in high school. Another two stories for comparison - just stories, not meant for scientific conclusions. Early in the U.S. course of infection, we applied for "compassionate use" of remdesivir, an antiviral, for two of our severely infected patients. (Since then, due to overwhelming demand, the drug is no longer available for "compassionate use," though there are now clinical trials open to enrollment.) We do not know whether remdesivir is helpful in coronavirus, but now that there are trials, we wait to see whether, how, and when it should be given.
The first patient had been struggling with COVID for a week when his profound oxygen failure required him to be put on a ventilator. At the time, China had just started a clinical trial for remdesivir, and a patient in Washington State had just received it. With great hope, we gave him the drug, but unfortunately, it made no difference. He continued to require escalating amounts of life support. As an intensive care physician, I often experience this feeling, hovering at the limits of medicine, offering a final potential therapy, and finding it wanting. It's a hard conversation to have with family; bringing up a last-ditch effort offers hope, though we really don't know what will happen. We temper our expectations, but still, we are almost always let down.
The second patient, also severely ill with COVID, flirted each day with the need to be intubated and put on a mechanical ventilator. He was younger, and around this time, we began hearing scattered reports of life-threatening organ failure in young patients. Although we know age correlates strongly with mortality, there are still patients in their twenties and thirties dying from this disease. We applied for and gave him the remdesivir. Within twelve hours, he had a dramatic improvement. He went from bedbound and continuously short of breath to sitting in a chair, texting on his cell phone. We were shocked. I can't think of many other situations that turn around so fast.
Remember Milo from Norton Juster's
The Phantom Tollbooth whose assumptions carry him, the Humbug, and Tock to the Island of Conclusions? How easy it is to hear these two stories, or to see these two patients, and to desire so blazingly for this drug to work. Or to feel that we have crossed some threshold with this disease so rapid and terrifying that we can justify unproven last resorts. After all, if someone is that ill, what harm can come of just trying something - in case it works?
Though I understand that feeling, I don't think it is a rational or appropriate way to practice medicine. We have a history riddled with examples of interventions that seemed sound and had anecdotal benefit that later proved to be nonbeneficial after controlled clinical trials (hormone replacement therapy comes to mind). Individual case reports are too subject to irrational conclusions. As a recent JAMA viewpoint states, "a common interpretation...is that if the patient died, they died from the disease, but if the patient survived, they survived because of the given drug. This is not true" (Kalil, 2020).
Furthermore, in a disease that threatens to overwhelm our health care system and its resources, we need to focus on those things that we know will save someone's life without being distracted or bogged down by things that might or might not. It's easy to ascribe medications miracle properties, but without controlled trials, we don't know why one patient improves and another does not. There's a lot out there, especially on social media, on hydroxychloroquine, antivirals, interferon, and other possible therapies. All of these medications have side effects, and many of these side effects are life threatening, especially for the critically ill patient. COVID-19 can cause cardiac failure, liver injury, and bone marrow suppression, and many of these drugs can worsen those effects. Are we helping or are we causing harm?
Clinical trials, despite being cumbersome, time-consuming, and laden with disclaimers, do offer us a measure of hope. Without them, we cannot know who benefits and who is harmed, or even what those benefits or harms may be. In a pandemic like this, anxiety and urgency may send us flying to the Island of Conclusions, and I am grateful for those scientists and researchers who ground us, reminding me that there is an established method for us explorers forging past the boundaries of the known as we tackle a novel and scary disease.